Family: Euphorbiaceae
Genus: Phyllanthus
Species: niruri, amarus
Synonyms: Phyllanthus carolinianus, P, sellowianus, P. fraternus, P. kirganella, P. lathyroides, P. lonphali, Nymphanthusniruri Common Names: Chanca piedra, quebra pedra, stone-breaker, arranca-pedras, punarnava, amli, bhonya, bhoomi amalaki, bhui-amla, bhui amla, bhuianvalah, bhuimy-amali, bhuin-amla, bhumyamalaki, cane peas senna, carry-me-seed, creole senna, daun marisan, derriere-dos, deye do, erva-pombinha, elrageig, elrigeg, evatbimi, gale-wind grass, graine en bas fievre, hurricane weed, jar-amla, jar amla, kizha nelli, malva-pedra, mapatan,para-parai mi, paraparai mi, pei, phyllanto, pombinha, quinine weed, sacha foster, cane senna, creole senna, shka-nin-du, viernes santo, ya-taibai, yaa tai bai, yah-tai-bai, yerba de san pablo
Part Used: Entire plant
Chanca piedra is a small, erect, annual herb that grows 30–40 cm in height. It is indigenous to the rainforests of the Amazon and other tropical areas throughout the world, including the Bahamas, southern India, and China. P. niruri is quite prevalent in the Amazon and other wet rainforests, growing and spreading freely (much like a weed). P. amarus and P. sellowianus are closely related to P. niruri in appearance, phytochemical structure, and history of use, but typically are found in the drier tropical climates of India, Brazil, and even Florida and Texas.
The Phyllanthus genus contains over 600 species of shrubs, trees, and annual or biennial herbs distributed throughout the tropical and subtropical regions of both hemispheres. Unfortunately, there remains a great deal of confusion among scientists regarding plant identification and, in many cases, plant misidentification makes evaluation of published information difficult. P. amarus (Thonn. & Schum) and P. sellowianus are often considered a variety of P. niruri, or no distinction is made among these three species in published clinical research. Oftentimes one name is indicated to be synonymous with another and, sometimes, both names are used interchangeably as if referring to one plant. It became so confusing that, in the 1990s, a major reorganization of the Phyllanthus genus was conducted (which classified P. amarus as a type of P. niruri).
TRIBAL AND HERBAL MEDICINE USES
The Spanish name of the plant, chanca piedra, means “stone breaker” or “shatter stone.” It was named for its effective use to generations of Amazonian indigenous peoples in eliminating gallstones and kidney stones. In Brazil, the plant is known as quebra-pedra or arranca-pedras (which also translates to “break-stone”). In addition to kidney stones, the plant is employed in the Amazon for numerous other conditions by the indigenous peoples, including colic, diabetes, malaria, dysentery, fever, flu, tumors, jaundice, vaginitis, gonorrhea, and dyspepsia. Based on its long documented history of use in the region, the plant is generally employed to reduce pain, expel intestinal gas, to stimulate and promote digestion, to expel worms, as a mild laxative.
Chanca piedra has a long history in herbal medicine systems in every tropical country where it grows. For the most part, it is employed for similar conditions worldwide. Its main uses are for many types of biliary and urinary conditions including kidney and gallbladder stones; for hepatitis, colds, flu, tuberculosis, and other viral infections; liver diseases and disorders including anemia, jaundice and liver cancer; and for bacterial infections such as cystitis, prostatitis, venereal diseases and urinary tract infections. It is also widely employed for diabetes and hypertension as well as for its diuretic, pain-relieving, digestive stimulant, antispasmodic, fever reducing, and cellular protective properties in many other conditions.
PLANT CHEMICALS
Since the mid-1960s, chanca piedra has been the subject of much phytochemical research to determine the active constituents and their pharmacological activities. It is a rich source of plant chemicals, including many which have been found only in the Phyllanthus genus. Many of the "active" constituents are attributed to biologically active lignans, glycosides, flavonoids, alkaloids, ellagitannins, and phenylpropanoids found in the leaf, stem, and root of the plant. Common lipids, sterols, and flavonols also occur in the plant.
The main plant chemicals in chanca piedra include alkaloids, astragalin, brevifolin, carboxylic acids, corilagin, cymene, ellagic acid, ellagitannins, gallocatechins, geraniin, hypophyllanthin, lignans, lintetralins, lupeols, methyl salicylate, niranthin, nirtetralin, niruretin, nirurin, nirurine, niruriside, norsecurinines, phyllanthin, phyllanthine, phyllanthenol, phyllochrysine, phyltetralin, repandusinic acids, quercetin, quercetol, quercitrin, rutin, saponins, triacontanal, and tricontanol.
BIOLOGICAL ACTIVITIES AND CLINICAL RESEARCH
It is little wonder that chanca piedra is used for so many purposes in herbal medicine systems: in clinical research over the years, the plant has demonstrated liver protective, antilithic (expels stones), pain-relieving, hypotensive, antispasmodic, antiviral, antibacterial, diuretic, antimutagenic, and hypoglycemic activities. Due of the confusion among P. niruri, P. amarus, and P. sellowianus over the years (and the reclassification of the genus), the research reviewed herein will encompass that which has been reported on all three of these very similar species.
The first notable area of study has validated chanca piedra's longstanding traditional use for kidney stones. In 1990, the Paulista School of Medicine in S?o Paulo, Brazil, conducted studies with humans and rats with kidney stones. They were given a simple tea of chanca piedra for 1-3 months and it was reported that the tea promoted the elimination of stones. They also reported a significant increase in urine output as well as sodium and creatine excretion. Subsequently the medical school educated new doctors about the ability to treat kidney stones with this natural remedy and now it is found in many pharmacies throughout Brazil.
In a 1999 in vitro clinical study, a chanca piedra extract exhibited the ability to block the formation of calcium oxalate crystals (the building blocks of most kidney stones) which indicates that it might be a useful preventative aid for people with a history of kidney stones. In a 2002 in vivo study, researchers seeded the bladders of rats with calcium oxalate crystals and treated them for 42 days with a water extract of chanca piedra. Their results indicated that chanca piedra strongly inhibited the growth and number of stones formed over the control group. Several of the animals even passed the stones which did form. Most recently (in 2003), scientists again confirmed in vitro that chanca piedra could help prevent the formation of kidney stones stating, ". . . that it may interfere with the early stages of stone formation and may represent an alternative form of treatment and/or prevention of urolithiasis."
Previously (in the mid-1980s) the antispasmodic activity of chanca piedra was reported. This led researchers to surmise that "smooth muscle relaxation within the urinary or biliary tract probably facilitates the expulsion of kidney or bladder calculi." Researchers had already reported chanca piedra's antispasmodic properties and smooth muscle relaxant properties (including a uterine relaxant effect) in earlier studies. In 1990, Nicole Maxwell reported that Dr. Wolfram Wiemann (of Nuremburg, Germany) treated over 100 kidney stone patients with chanca piedra obtained in Peru and found it to be 94% successful in eliminating stones within a week or two.
Chanca piedra is also used in herbal medicine for gallstones and, while no research has been performed that specifically validated this use, one study does indicate that chanca piedra has an effect on gallbladder processes. In a 2002 study, Indian researchers reported that chanca piedra increased bile acid secretion in the gallbladder and significantly lowered blood cholesterol levels in rats. The beneficial effects of lowering cholesterol and triglyceride levels was also confirmed by another in vivo (rat) study in 1985.
The plant's traditional use for hypertension has been explored by research as well. The hypotensive effects were first reported in a dog study in 1952 (in which a diuretic effect was noted also). The hypotensive effects were attributed to a specific phytochemical in chanca piedra called geraniin in a 1988 study. In 1995 Indian researchers gave human subjects with high blood pressure chanca piedra leaf powder in capsules and reported a significant reduction in systolic blood pressure, a significant increase in urine volume and sodium excretion. Chanca piedra's diuretic effect in humans was recorded as far back as 1929 and, in India, a tablet of chanca piedra (called Punarnava) is sold as a diuretic there.
In the above 1995 study, researchers also reported that blood sugar levels were reduced significantly in human subjects studied. Two other studies with rabbits and rats document the hypoglycemic effect of chanca piedra in diabetic animals. Yet another study documented chanca piedra with aldose reductase inhibition (ARI) properties. Aldose reductases are substances that act on nerve endings exposed to high blood sugar concentration and can lead to diabetic neuropathy and macular degeneration. Substances which inhibit these substances can prevent some of the chemical imbalances that occur and thus protect the nerve. This ARI effect of chanca piedra was attributed, in part, to a plant chemical called ellagic acid. This well-studied plant chemical has been documented with many other beneficial effects in numerous clinical studies (over 300 to date).
Another area of research has focused on the pain-relieving effects of chanca piedra and performed at a Brazilian university. So far, they've published six studies on their findings. The first three studies reported strong and dose-dependent pain-relieving effects in mice given extracts of chanca piedra against six different laboratory-induced pain models. In 1996, they isolated and tested chanca piedra's hypotensive plant chemical geraniin and reported that it was seven times more potent as a pain-reliever than aspirin or acetaminophen. Their last two studies (published in 2000) continued to document chanca piedra's pain-relieving effects against normal pain models in mice, and, newly-tested nerve-related pain models. Again, they related this effect to the geraniin plant chemical and reported its ability to inhibit several neurotransmitter processes that relay and receive pain signals in the brain. Unlike aspirin (which can harm the mucosal lining of the stomach and cause ulcers), geraniin has been reported to have antiulcerous properties and to protect the gastric tract instead. This pain-relieving effect is probably why so many people taking chanca piedra for kidney stones (a very painful affair) report such quick relief and long before chanca piedra could actually break down and expel a stone.
The liver-protecting activity of chanca piedra is another subject which has been established with clinical research with animals and humans. These effects have been attributed to (at least) two novel plant chemicals in chanca piedra named phyllanthin and hypophyllanthin. The researchers who reported the cholesterol-lowering effects also reported that chanca piedra protected rats from liver damage induced by alcohol, and normalized a "fatty liver." One in vitro study and four in vivo studies (with rats and mice) document that extracts of chanca piedra effectively protect against liver damage from various chemical liver toxins. Two human studies reported chanca piedra's liver protective and detoxifying actions in children with hepatitis and jaundice. Indian researchers reported that chanca piedra was an effective single drug in the treatment of jaundice in children, and British researchers reported that children treated with a chanca piedra extract for acute hepatitis had liver function return to normal within five days. Researchers in China also reported liver protective actions when chanca piedra was given to adults with chronic hepatitis.
A 2000 study even documented that chanca piedra increased the life span of mice with liver cancer from thirty-tree weeks (control group without treatment) to fifty-two weeks. Another research group tried to induce liver cancer in mice that had been pre-treated with a water extract of chanca piedra. Their results indicated the chanca piedra extract dose-dependently lowered tumor incidence, levels of carcinogen-metabolizing enzymes, levels of liver cancer markers, and liver injury markers. Both studies indicate that the plant has a better ability to prevent and slow down the growth of tumors rather than a direct toxic effect or ability to kill cancer cells.
It may well be that chanca piedra's documented ability to stop cells from mutating plays an important factor in this reported anticancerous activity. In several animal studies (as well as within cell cultures), extracts of chanca piedra have stopped or inhibited cells (including liver cells) from mutating in the presence of chemical substances known to create cellular mutations and DNA strand breaks (which can lead to the creation of cancerous cells). Again, one of these studies indicated that chanca piedra inhibited several enzyme processes peculiar to cancer cells' replication and growth-rather than a direct toxic effect of killing the cancer cell (sarcoma, carcinoma, and lymphoma cells were studied). This cellular-protective quality was evidenced in other research which indicated that chanca piedra protected against chemically-induced bone marrow damage in mice, as well as against radiation-induced damage in mice.
The last area of published research (which is the most extensive and the most confusing) concerns chanca piedra's antiviral properties. Both human and animal studies indicate that chanca piedra can protect the liver, even during hepatitis infection. Chanca piedra has also been reported to have direct antiviral activity in human, animal, and test tube studies against the Hepatitis B virus. Over 20 clinical studies have been published to date about these effects, and the results have been inconsistent and confusing (unless thoroughly evaluated).
Hepatitis is enough of a worldwide concern to merit sifting through the disparate studies. Hepatitis B infection (HBV) is the leading cause of liver cancer worldwide - which is considered 100% fatal. Carriers of HBV are 200 times more likely to develop liver cancer decades after initial infection. Many people who contract HBV become chronic (and, often, asymptomatic) carriers of the disease while still being contagious to others. HBV is reported to be 100 times more infectious than HIV and, like HIV, is transmitted through blood transfusions, needles, sexual contact, and in utero (from mother to child in the womb). Statistics on HBV are staggering: one out of every 250 Americans are HBV carriers! The Center for Disease Control (CDC) estimates that 200,000 new U.S. cases of HBV infection per year are added to the current estimate of one million carriers in the U.S. (and an estimated 300 million worldwide). The CDC also reports that (in the U.S.) 3,000 - 4,000 annual deaths from cirrhosis and 1,000 deaths from liver cancer are HBV-related. So when Dr. Baruch Blumberg reported that chanca piedra could clear up the chronic carrier state of Hepatitis B in 1988, it was a big deal. Dr. Blumberg was the winner of the 1963 Nobel Prize for discovering the HBV antigen in the first place. This led to the discovery that HBV was the primary cause of liver cancer and initiated the development of HBV vaccines.
Most of Blumberg's early research was carried out in India in collaboration with an Indian research group. Their first human study reported that a water extract of Phyllanthus amarus cleared the HBV surface antigen from 22 of 37 chronic HBV patients in only 30 days (and they continued to test negative for 9 months, at which time the report was published). This same group had published several earlier in vitro studies as well as animal (woodchuck) studies. (Woodchucks respond to chronic HBV infection in much the same manner as do humans which is why they are chosen for such research). All reported similar and effective anti-HBV effects. By that time, Blumberg was employed with the Fox Chase Cancer Center in Philadelphia; he, Fox Chase, and the Indian researchers filed two patents on the plant's ability to treat HBV and its antiviral properties in 1985 and 1988 (now calling the plant P. niruri). The first patent was specific to HBV; the second stated that the plant's antiviral properties were achieved in part through a strong inhibition of reverse transcriptase (chemicals necessary for many types of viruses to grow) which made it possible to treat such retroviruses as HIV and sarcoma and leukemia viruses.
It was also during this time that the group developed a new and "better" extraction process. This process involved multiple, complicated extractions in which the plant was first soaked in cold water, then the resulting fluid was extracted first in hexane, then in benzene, then in methanol, and back into water. Their documentation revealed, however, that they didn't know specifically what the active chemicals were in the final extract that were providing the antiviral effects! While it was certainly a complicated and patentable process, much of the subsequent published research by this group throughout the 1990s using this new, patented "water extract" conflicted with their earlier studies, and was not as effective in the in vivo research for HBV. This caused much confusion as to whether chanca piedra (P. niruri or P. amarus) was an effective treatment or not. To add to the confusion, in 1994, a New Zealand research group prepared a chemically-altered extract (of P. amarus) which was standardized to the geraniin chemical content (the chemical documented with analgesic and hypotensive properties). They started a double-blind HBV human trial, later discontinued it due to lack of response, and published another negative result study.
Meanwhile, a separate research group in China (where HBV is wide-spread) working with a straight water extract and/or herb powder published two positive studies showing good results with human HBV patients in 1994 and 1995. Their second study suggested that different results were obtained through different Phyllanthus species of plants used (and that yet another species - P. urinaria provided the best anti-HBV results). The Chinese published a more recent (2001) study which compared 30 chronic HBV patients taking a chanca piedra extract to 25 patients taking interferon (the leading conventional drug used for HBV) for three months. Both treatments showed an equal effectiveness of 83%, but the chanca piedra group rated significantly higher in the normalization of liver enzymes and recovery of liver function than the interferon-treated group. They published yet another study in 2003 which attributed the anti-HVB effects mainly to four chemicals in chanca piedra: niranthin, nirtetralin, hinokinin, and geraniin.
Finally, The Cochrane Hepato-Biliary Research Group in Copenhagen reviewed all the HBV published research (22 randomized trials) and published an independent review of the results. It stated that treatment with "Phyllanthus herb" (they acknowledged the confusion among the various species used) had "a positive effect on clearance of serum HBsAg" (HBV surface antigen) comparable to interferon and was better than nonspecific treatment or other herbal medicines for HBV and liver enzyme normalization." They also indicated that large trials were warranted due to these documented positive effects and the lack of standardization of the research methods and plant species used in the various published studies to date.
Concerned with HIV specifically, a Japanese research group reported that a simple water extract of P. niruri inhibited HIV-1 reverse transcriptase in 1992. (Several conventional drugs used today against HIV are classified as "reverse transcriptase inhibitors.") They attributed this effect to a plant chemical in chanca piedra called repandusinic acid A. When they tested this chemical individually it demonstrated significant toxicity to HIV-1 at very small dosages (a 90% in vitro inhibition using only 2.5 mcg). Bristol-Myers Squibb Pharmaceutical Research Institute isolated yet another chemical in chanca piedra with anti-HIV actions-a novel compound that they named niruriside and described in a 1996 study. A German research organization published their first study on chanca piedra and its application with HIV therapy (reporting a 70-75% inhibition of virus) in 2003. In addition to these antiviral properties, the plant has also been documented other antimicrobial effects. Chanca piedra demonstrated in vitro antibacterial actions against Staphylococcus, Micrococcus, and Pasteurella bacteria as well as in vivo and in vitro antimalarial properties, which validates other traditional uses.
CURRENT PRACTICAL USES
Chanca piedra is a perfect example of a highly beneficial medicinal plant which is deserving of much more research - but one which is fraught with the typical problems of working with a complicated, chemically-rich plant. Unless a major (and well-funded) pharmaceutical or research company can isolate a single, patentable chemical (or can come up with a patentable extraction process that actually works as well as a simple water extract) to justify the high cost of research, chanca piedra probably will remain in the "unproven herbal remedy" category. There just aren't enough non-profit dollars or government grant funds available to fund research on natural plant extracts that can't be patented. Since chanca piedra's many biological activities and benefits are attributed to many different chemicals (whose synergistic interactions are unclear), and most seem to be completely water soluble (no complicated and patentable manufacturing processes necessary), for-profit research dollars will probably be spent elsewhere. It is yet another perfect example that Mother Nature is infinitely a better chemist; the natural herb continues to work better than any man-made chemically altered (and patentable) extracts.
But what a natural remedy it is! With its applications for kidney stones and gallstones, cellular and liver protection, hypertension and high cholesterol, cancer prevention, and its pain-relieving and antiviral effects, it is gaining in popularity on many continents as an effective herbal remedy. It's also important to note that in all the research published over the last 20 years, no signs of toxicity or side effects have been reported in any of the human or animal studies, even in acute or chronic use.
Rain-tree is responsible for the manufacturing of Chanca piedr and they take full responsibly for their claims.